 |
0 Diseases |  |
137 Trials |
|
137 Trials |  |
5343 News |  |
| «12...7980818283848586878889...9091» |
- | Trial completion date, Trial primary completion date: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (clinicaltrials.gov) - May 20, 2019
P4, N=1786, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial completion date: Sep 2019 --> Sep 2020 | Trial primary completion date: Jun 2019 --> Sep 2020
- ||||||| murepavadin (POL7080) / Spexis
Trial suspension: PRISM-MDR: Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa (clinicaltrials.gov) - May 15, 2019
P3, N=150, Suspended, Sponsor: Polyphor Ltd.
Trial completion date: Sep 2019 --> Sep 2020 | Trial primary completion date: Jun 2019 --> Sep 2020 Recruiting --> Suspended
- | levofloxacin / Generic mfg.
Trial completion date, Trial primary completion date: Procalcitonin-guided Antibiotic Therapy During Severe Exacerbation of COPD (clinicaltrials.gov) - May 13, 2019
P=N/A, N=100, Recruiting, Sponsor: University Hospital, Mahdia
Recruiting --> Suspended Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Oct 2019 --> Oct 2020
- || Enrollment change, Trial withdrawal: DRAMATIC: Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB (clinicaltrials.gov) - May 7, 2019
P3, N=0, Withdrawn, Sponsor: Boston University
Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Oct 2019 --> Oct 2020 N=465 --> 0 | Not yet recruiting --> Withdrawn
- | New P2 trial: Effect of Topical Sinonasal Antibiotics (clinicaltrials.gov) - May 1, 2019
P2, N=40, Not yet recruiting, Sponsor: United States Naval Medical Center, San Diego
- |||||||||| levofloxacin / Generic mfg.
New P3 trial, Combination therapy: Helicobacter pylorie eradication with Probiotic Lactobacillus casei rhamnosus LCR35 Alone or in Combination with Antibiotic Therapy (EUDRACT) - Apr 25, 2019
P3, N=440, Ongoing, Sponsor: Medical University Innsbruck
- | Gatiflox (gatifloxacin) / Orient Europharma, NN1213 / Novo Nordisk, Besivance (besifloxacin ophthalmic suspension) / Bausch Health
Trial completion date, Trial primary completion date: Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis (clinicaltrials.gov) - Apr 19, 2019
P3, N=252, Recruiting, Sponsor: University Hospital, Geneva
N=465 --> 0 | Not yet recruiting --> Withdrawn Trial completion date: Aug 2018 --> Aug 2021 | Trial primary completion date: Mar 2018 --> Mar 2021
- | levofloxacin / Generic mfg.
Trial initiation date: TriDoRe: Novel Triple-dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More (clinicaltrials.gov) - Apr 18, 2019
P3, N=3000, Not yet recruiting, Sponsor: Institute of Tropical Medicine, Belgium
Trial completion date: Aug 2018 --> Aug 2021 | Trial primary completion date: Mar 2018 --> Mar 2021 Initiation date: Apr 2019 --> Sep 2019
- ciprofloxacin / Generic mfg., meropenem / Generic mfg., Daewon Pharmaceutical, Garamycin (gentamicin sulfate) / Generic mfg.
A study of antimicrobial resistance phenotype prediction using whole-genome sequencing analysis in Escherichia coli () - Apr 5, 2019 - Abstract #ECCMID2019ECCMID_2532;
However, specificity for ampicillin and ampicillin/sulbactam were not good. The estimation of aminoglycoside resistance from genotype did not work.
- | NN1213 / Novo Nordisk
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Comparison of Two Rescue Therapies for Helicobacter Pylori Infection (clinicaltrials.gov) - Mar 14, 2019
P=N/A, N=51, Completed, Sponsor: Kaohsiung Veterans General Hospital.
The estimation of aminoglycoside resistance from genotype did not work. Recruiting --> Completed | N=160 --> 51 | Trial completion date: Nov 2016 --> Oct 2017 | Trial primary completion date: Nov 2016 --> Jul 2017
- | levofloxacin / Generic mfg., tetracycline / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Levofloxacin Triple and Bismuth Quadruple Therapies for Rescue Treatment of H Pylori Infection (clinicaltrials.gov) - Mar 14, 2019
P=N/A, N=102, Completed, Sponsor: Kaohsiung Veterans General Hospital.
Recruiting --> Completed | N=160 --> 51 | Trial completion date: Nov 2016 --> Oct 2017 | Trial primary completion date: Nov 2016 --> Jul 2017 Recruiting --> Completed | Trial completion date: Jun 2017 --> Sep 2017 | Trial primary completion date: Feb 2017 --> Sep 2017
- | levofloxacin / Generic mfg.
Enrollment open, Nontuberculous mycobacteria: Linezolid for Treatment of Nontuberculous Mycobacterial Diseases (clinicaltrials.gov) - Mar 11, 2019
P4, N=40, Recruiting, Sponsor: Mahidol University
Recruiting --> Completed | Trial completion date: Jun 2017 --> Sep 2017 | Trial primary completion date: Feb 2017 --> Sep 2017 Not yet recruiting --> Recruiting
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Trial completion date, Trial primary completion date: SMILE: Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization (clinicaltrials.gov) - Mar 11, 2019
P4, N=54, Completed, Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial completion date: Apr 2020 --> Jul 2018 | Trial primary completion date: Apr 2020 --> Jul 2018
- | levofloxacin / Generic mfg., amikacin sulfate / Generic mfg.
New trial: TB-TRUST: Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T) (clinicaltrials.gov) - Mar 7, 2019
P=N/A, N=220, Not yet recruiting, Sponsor: Huashan Hospital
- | levofloxacin / Generic mfg.
New P3 trial: TriDoRe: Novel Triple-dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More (clinicaltrials.gov) - Mar 5, 2019
P3, N=3000, Not yet recruiting, Sponsor: Institute of Tropical Medicine, Belgium
- | NN1213 / Novo Nordisk
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: RCT(Randomized Clinical Trial ) of Antibiotic Therapy in Chronic Endometritis (clinicaltrials.gov) - Feb 25, 2019
P=N/A, N=114, Completed, Sponsor: Fu Xing Hospital, Capital Medical University
Recruiting --> Completed | Trial completion date: Apr 2020 --> Jul 2018 | Trial primary completion date: Apr 2020 --> Jul 2018 Recruiting --> Completed | N=82 --> 114 | Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018
- | ciprofloxacin oral / Generic mfg., levofloxacin / Generic mfg.
New P2 trial: Ciprofloxacin Versus Levofloxacin in Stem Cell Transplant (clinicaltrials.gov) - Feb 21, 2019
P2, N=308, Recruiting, Sponsor: Henry Ford Health System
- | levofloxacin / Generic mfg.
New P4 trial: Intraluminal Mono-antibiotic Therapy for Helicobacter Pylori Infection - A Comparison of Levofloxacin Powder and Levofloxacin Solution (clinicaltrials.gov) - Feb 6, 2019
P4, N=50, Not yet recruiting, Sponsor: Mackay Memorial Hospital
- | Trial completion date, Trial primary completion date: Treatment Shortening of MDR-TB Using Existing and New Drugs (clinicaltrials.gov) - Feb 4, 2019
P2, N=238, Recruiting, Sponsor: Seoul National University Hospital
Recruiting --> Completed | N=82 --> 114 | Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018 Trial completion date: Dec 2019 --> Jun 2021 | Trial primary completion date: Dec 2019 --> Jun 2021
- |||||||||| New P3 trial: DRAMATIC: Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB (clinicaltrials.gov) - Feb 4, 2019
P3, N=465, Not yet recruiting, Sponsor: Boston University
- | levofloxacin / Generic mfg., amoxycillin/clavulanate / Generic mfg.
Trial termination: Early Stoppage Versus Continuation of Antimicrobial Therapy in Low Risk Pediatric Cancer Patients With Febrile Neutropenia, Before Recovery of Counts: -DALFEN Study (clinicaltrials.gov) - Feb 1, 2019
P3, N=142, Terminated, Sponsor: All India Institute of Medical Sciences, New Delhi
Trial completion date: Dec 2019 --> Jun 2021 | Trial primary completion date: Dec 2019 --> Jun 2021 Recruiting --> Terminated; poor accrual
- | levofloxacin / Generic mfg., voriconazole / Generic mfg.
Trial completion date, Trial initiation date, Trial primary completion date: Prevention of Oral Mucositis After Using Oral Topical Vitamin E Versus Voriconazole and Levofloxacin in Pediatric Cancer Patients Receiving Chemotherapy (clinicaltrials.gov) - Jan 31, 2019
P=N/A, N=15, Enrolling by invitation, Sponsor: Cairo University
Recruiting --> Terminated; poor accrual Trial completion date: Sep 2019 --> Sep 2020 | Initiation date: Jan 2019 --> Jan 2020 | Trial primary completion date: Jun 2019 --> Jun 2020
- | Lamprene (clofazimine) / Novartis, Sirturo (bedaquiline) / J&J, Pharmstandard, NN1213 / Novo Nordisk
Enrollment change, Trial completion date: STREAM: The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB (clinicaltrials.gov) - Jan 29, 2019
P3, N=530, Recruiting, Sponsor: IUATLD, Inc
Trial completion date: Sep 2019 --> Sep 2020 | Initiation date: Jan 2019 --> Jan 2020 | Trial primary completion date: Jun 2019 --> Jun 2020 N=1155 --> 530 | Trial completion date: Dec 2021 --> Jun 2022
- | levofloxacin / Generic mfg., trimethoprim/sulfamethoxazole / Generic mfg., azithromycin / Generic mfg.
Trial completion, Enrollment change: Fluoroquinolone Associated Disability (clinicaltrials.gov) - Jan 29, 2019
P=N/A, N=239306, Completed, Sponsor: Janssen Research & Development, LLC
N=1155 --> 530 | Trial completion date: Dec 2021 --> Jun 2022 Recruiting --> Completed | N=100 --> 239306
- | Sufenta (sufentanil) / Akorn
Trial completion date, Trial primary completion date: Population Pharmacokinetics of Teicoplanin, Levofloxacin, Piperacillin/Tazobactam, Meropenem, Vancomycin, Remifentanil, Cefepime, Cefpirome, Sufentanil, Midazolam, Clopidogrel, Ticagrelor, Prasugrel During Veno-arterial Extracorporeal Membrane Oxygenation (VA ECMO) (clinicaltrials.gov) - Jan 28, 2019
P=N/A, N=70, Recruiting, Sponsor: Yonsei University
Recruiting --> Completed | N=100 --> 239306 Trial completion date: Dec 2016 --> Dec 2019 | Trial primary completion date: Dec 2016 --> Dec 2019
- | amoxicillin / Generic mfg.
New trial: Daily Four Times or Two Times Usage of PPI and Amoxicillin for the First or Second Line H. Pylori Eradication (clinicaltrials.gov) - Jan 14, 2019
P=N/A, N=530, Enrolling by invitation, Sponsor: Chang Gung Memorial Hospital
- | levofloxacin / Generic mfg., fluconazole oral / Generic mfg., acyclovir / Generic mfg.
Trial suspension, Trial primary completion date, IO biomarker: ZENITH: Zinc as Enhancer in Immune Recovery After Stem Cell Transplantation for Hematological Malignancies (clinicaltrials.gov) - Jan 10, 2019
P2, N=50, Suspended, Sponsor: Azienda Ospedaliero, Universitaria Pisana
Trial completion date: Dec 2016 --> Dec 2019 | Trial primary completion date: Dec 2016 --> Dec 2019 Recruiting --> Suspended | Trial primary completion date: Jan 2018 --> Jan 2019
- Sirturo (bedaquiline) / J&J, Pharmstandard
Trial completion, Trial completion date, Trial primary completion date: An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB) (clinicaltrials.gov) - Dec 28, 2018
P2, N=6, Completed, Sponsor: Janssen Pharmaceutical K.K.
Recruiting --> Suspended | Trial primary completion date: Jan 2018 --> Jan 2019 Active, not recruiting --> Completed | Trial completion date: Sep 2020 --> Nov 2018 | Trial primary completion date: Jul 2018 --> Nov 2018
- | New trial: Efficacies of Two Bismuth Quadruple Therapies in the Second-line Treatment of H Pylori Infection (clinicaltrials.gov) - Dec 19, 2018
P=N/A, N=184, Recruiting, Sponsor: Ping-I (William) Hsu, M.D.
- | levofloxacin / Generic mfg., tetracycline / Generic mfg.
New P3 trial: Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies (clinicaltrials.gov) - Dec 19, 2018
P3, N=918, Recruiting, Sponsor: Kaohsiung Veterans General Hospital.
- ||||||| Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
Trial completion: Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections (clinicaltrials.gov) - Dec 11, 2018
P3, N=908, Completed, Sponsor: Tetraphase Pharmaceuticals, Inc.
Active, not recruiting --> Completed | Trial completion date: Sep 2020 --> Nov 2018 | Trial primary completion date: Jul 2018 --> Nov 2018 Active, not recruiting --> Completed
- | levofloxacin / Generic mfg., clarithromycin / Generic mfg.
Enrollment change, Trial withdrawal: Comparison Efficacy of 14-day Concomitant Therapy:Clarithromycin vs.Levofloxacin in Eradication of H.Pylori (clinicaltrials.gov) - Dec 7, 2018
P4, N=0, Withdrawn, Sponsor: Damascus Hospital
Active, not recruiting --> Completed N=100 --> 0 | Recruiting --> Withdrawn
- ||| Nuzyra (omadacycline) / Paratek
Enrollment open: IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis (clinicaltrials.gov) - Dec 3, 2018
P2, N=200, Recruiting, Sponsor: Paratek Pharmaceuticals Inc
N=100 --> 0 | Recruiting --> Withdrawn Not yet recruiting --> Recruiting
- | Nuzyra (omadacycline) / Paratek
New P2 trial: IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis (clinicaltrials.gov) - Nov 27, 2018
P2, N=200, Not yet recruiting, Sponsor: Paratek Pharmaceuticals Inc
- | levofloxacin / Generic mfg.
Trial initiation date: Clinical Study of Sanjin Tablets for the Treatment of Acute Simple Lower Urinary Tract Infection (clinicaltrials.gov) - Nov 26, 2018
P4, N=252, Not yet recruiting, Sponsor: China Academy of Chinese Medical Sciences
Not yet recruiting --> Recruiting Initiation date: Sep 2018 --> Jan 2019
- | levofloxacin / Generic mfg., fosfomycin tromethamine / Generic mfg.
Enrollment open: Safety and Efficacy Study of Oral Fosfomycin Versus Oral Levofloxacin to Treat Complicated Urinary Syndromes (FOCUS) (clinicaltrials.gov) - Nov 16, 2018
P4, N=634, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Initiation date: Sep 2018 --> Jan 2019 Not yet recruiting --> Recruiting
- | tobramycin/dexamethasone / Generic mfg., levofloxacin / Generic mfg.
New P3 trial, Surgery: LEADER7: Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery (clinicaltrials.gov) - Nov 14, 2018
P3, N=800, Recruiting, Sponsor: NTC srl
- | levofloxacin / Generic mfg.
New P2 trial, Surgery: iPERME: Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery (clinicaltrials.gov) - Nov 14, 2018
P2, N=120, Recruiting, Sponsor: NTC srl
- | levofloxacin / Generic mfg.
Enrollment change: Short Compared With Standard Duration of Antibiotic Treatment for AECOPD (clinicaltrials.gov) - Nov 1, 2018
P2, N=520, Recruiting, Sponsor: University of Monastir
Not yet recruiting --> Recruiting N=300 --> 520
- | NN1213 / Novo Nordisk, Noxafil (posaconazole) / Merck (MSD)
Trial completion date, Trial primary completion date: Observational Evaluation of Infective Risk in Myelodysplastic Syndrome Patients (clinicaltrials.gov) - Oct 23, 2018
P=N/A, N=1000, Recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
N=300 --> 520 Trial completion date: Mar 2018 --> Dec 2018 | Trial primary completion date: Mar 2018 --> Dec 2018
- | levofloxacin / Generic mfg.
Enrollment change, Trial completion date, Trial primary completion date: Short Antibiotic Treatment Versus Duration Guided by Markers of Inflammation in the Treatment of AECOPD (clinicaltrials.gov) - Oct 23, 2018
P2, N=520, Recruiting, Sponsor: University of Monastir
Trial completion date: Mar 2018 --> Dec 2018 | Trial primary completion date: Mar 2018 --> Dec 2018 N=300 --> 520 | Trial completion date: Jun 2017 --> Dec 2018 | Trial primary completion date: Dec 2016 --> Dec 2018
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: Personalized Treatment for Refractory H Pylori Infection (clinicaltrials.gov) - Oct 12, 2018
P=N/A, N=150, Recruiting, Sponsor: Kaohsiung Veterans General Hospital.
N=300 --> 520 | Trial completion date: Jun 2017 --> Dec 2018 | Trial primary completion date: Dec 2016 --> Dec 2018 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
- | Actemra IV (tocilizumab) / Roche, JW Pharma, Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Kineret (anakinra) / SOBI
Enrollment open: Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants (clinicaltrials.gov) - Oct 10, 2018
P=N/A, N=500, Recruiting, Sponsor: Kevin Watt
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Not yet recruiting --> Recruiting
- | levofloxacin / Generic mfg.
New P2 trial: Short Compared With Standard Duration of Antibiotic Treatment for AECOPD (clinicaltrials.gov) - Oct 9, 2018
P2, N=300, Recruiting, Sponsor: University of Monastir
- | levofloxacin / Generic mfg., fosfomycin tromethamine / Generic mfg.
New P4 trial: Safety and Efficacy Study of Oral Fosfomycin Versus Oral Levofloxacin to Treat Complicated Urinary Syndromes (FOCUS) (clinicaltrials.gov) - Oct 4, 2018
P4, N=634, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- | levofloxacin / Generic mfg., prulifloxacin / Generic mfg.
Trial completion date, Trial primary completion date: Prulifloxacin in Chronic Bacterial Prostatitis (CBP) (clinicaltrials.gov) - Sep 28, 2018
P2, N=148, Recruiting, Sponsor: Aziende Chimiche Riunite Angelini Francesco S.p.A
Not yet recruiting --> Recruiting Trial completion date: Jun 2018 --> Jun 2020 | Trial primary completion date: Jun 2018 --> Jun 2020
- | Enrollment open: Topical Antibiotics in Chronic Rhinosinusitis (clinicaltrials.gov) - Sep 26, 2018
P1/2, N=40, Recruiting, Sponsor: Mayo Clinic
Trial completion date: Jun 2018 --> Jun 2020 | Trial primary completion date: Jun 2018 --> Jun 2020 Not yet recruiting --> Recruiting
- | Sivextro (tedizolid) / Merck (MSD), Nabriva Therap
Enrollment open, Trial initiation date: TEDIZOAM: Tedizolid Prolonged Treatment for Prosthetic Joint Infections (clinicaltrials.gov) - Sep 18, 2018
P=N/A, N=35, Recruiting, Sponsor: Tourcoing Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Jan 2018 --> Aug 2018
- | New P1/2 trial: Topical Antibiotics in Chronic Rhinosinusitis (clinicaltrials.gov) - Sep 17, 2018
P1/2, N=40, Not yet recruiting, Sponsor: Mayo Clinic
- | Enrollment change: InDEX: The Individualized M(X) Drug-resistant TB Treatment Strategy Study (clinicaltrials.gov) - Sep 6, 2018
P4, N=448, Recruiting, Sponsor: Centre for the AIDS Programme of Research in South Africa
Not yet recruiting --> Recruiting | Initiation date: Jan 2018 --> Aug 2018 N=300 --> 448